MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

Inclusion Criteria

• •1. Subject has histologically or cytologically confirmed diagnosis of advanced non-small cell lung cancer (stage IIIB or IV) or recurrent disease
• •2. Subject has received at least one line of prior therapy
• •3. Subjects with known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase receptor (ALK) or ROS1 gene rearrangements must have failed (progressive disease or unacceptable toxicity) at least one prior EGFR or ALK or ROS1 tyrosine kinase inhibitor, respectively. Subject may have received PD-1 or PDL-1 inhibitors and or chemotherapy. There is no limit on lines of prior anti-cancer therapy (a washout period applies for recent anti-cancer treatments).
• •4. Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion.
• •5. Subject is HLA-A\*02:01 or HLA-A\*02:06 positive.
• •6. Subject's tumor (either an archival specimen or a fresh biopsy if archival tissue is unavailable) has been pathologically reviewed by a designated central laboratory confirming MAGE-A10 expression.
• •7. Subject has an ECOG Performance Status 0-1 and anticipated life expectancy \>6 months prior to apheresis and \>3 months prior to lymphodepletion.
• •8. Subject is ≥18 to ≤75 years of age
• •9. Adequate organ function